This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 7-10, 2023 | In-Person + Digital
San Diego, CA, USAManchester Grand Hyatt San Diego

Hongchang Qu
Senior Director, Chemistry at Eli Lilly & Company


Dr. Qu is currently the Senior Director of the Peptide Therapeutic Group at Eli Lilly. Since he joined Lilly in 2013, he has led multiple preclinical peptide research projects and advanced them into clinical development to establish proof of concept. Prior to joining Eli Lilly, Dr. Qu was a Process Development Scientist for two years at the Polypeptide Laboratories. Dr. Qu holds a PhD degree in organic chemistry from the University of Arizona and had postdoctoral training at University of Pennsylvania.

Agenda Sessions

  • The Novel GIP, GLP-1, And Glucagon Triple Receptor Agonist LY3437943: From Discovery to Clinical Proof-of-Concept